Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarity
Things to check before joining
Study start dateStarted: December 16, 2019
Recruitment status
Terminated
Enrollment listed in the registry
10
Sponsor
Cerevel Therapeutics, LLC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT04232878
Official title
Show the full official title
A Phase 1, Double-Blind, Sponsor-Open, Placebo-Controlled, First-In-Human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Ascending Doses of CVL-936 In Healthy Subjects
Questions about this study?
The HopeStage team will email you.
Recruitment & locations
Terminated
Marlton
A listed location does not confirm current availability.
FAQ
Questions about this study
Who is behind this study?
The study sponsor is Cerevel Therapeutics, LLC.
Does this study involve medication?
Yes. The study involves medication, including CVL-936 and Matching Placebo.
Who can participate?
This study is for healthy volunteers. Listed age limits: 18 years to 50 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.